Ofatumumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06650 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 2 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 3 | follicular lymphoma | KG + DL |
| 4 | leukemia, lymphocytic, susceptibility to | KG + DL |
| 5 | chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 6 | metastatic neoplasm | KG + DL |
| 7 | malignant spiradenoma | KG + DL |
| 8 | Langerhans cell histiocytosis | KG + DL |
| 9 | histiocytic and dendritic cell neoplasm | KG + DL |
| 10 | childhood mediastinal neurogenic neoplasm | KG + DL |
| 11 | childhood germ cell tumor | KG + DL |
| 12 | childhood carcinoid tumor | KG + DL |
| 13 | Hodgkins lymphoma | KG + DL |
| 14 | optic nerve glioma | KG + DL |
| 15 | childhood ependymoma | KG + DL |
| 16 | childhood choroid plexus neoplasm | KG + DL |
| 17 | mantle cell lymphoma | KG + DL |
| 18 | neoplasm of mature B-cells | KG + DL |
| 19 | secondary interstitial lung disease in childhood and adulthood associated with a systemic vasculitis | KG + DL |
| 20 | childhood kidney neoplasm | KG + DL |
| 21 | secondary interstitial lung disease in childhood and adulthood associated with a metabolic disease | KG + DL |
| 22 | ALK+ histiocytosis | KG + DL |
| 23 | reticulohistiocytic granuloma | KG + DL |
| 24 | secondary interstitial lung disease specific to childhood associated with a systemic vasculitis | KG + DL |
| 25 | pulmonary sarcoidosis | KG + DL |
| 26 | small intestinal Burkitt lymphoma | KG + DL |
| 27 | precursor T-cell acute lymphoblastic leukemia | KG + DL |
| 28 | pediatric meningioma | KG + DL |
| 29 | small intestinal mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 30 | breast mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 31 | thyroid gland mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 32 | tonsillar lymphoma | KG + DL |
| 33 | Niemann-Pick disease type C | KG + DL |
| 34 | follicular lymphoma, susceptibility to, 1 | KG + DL |
| 35 | MALT lymphoma | KG + DL |
| 36 | B-cell neoplasm | KG + DL |
| 37 | obsolete Hodgkin’s granuloma | KG + DL |
| 38 | marginal zone lymphoma | KG + DL |
| 39 | extragonadal teratoma | KG + DL |
| 40 | B-cell prolymphocytic leukemia | KG + DL |
| 41 | plasma cell neoplasm | KG + DL |
| 42 | teratoma | KG + DL |
| 43 | precursor lymphoblastic lymphoma/leukemia | KG + DL |
| 44 | mature teratoma | KG + DL |
| 45 | lymphoplasmacytic lymphoma | KG + DL |
| 46 | ALK-positive large B-cell lymphoma | KG + DL |
| 47 | thymic epithelial neoplasm | KG + DL |
| 48 | Rubinstein-Taybi syndrome due to CREBBP mutations | KG + DL |
| 49 | acute lymphoblastic leukemia | KG + DL |
| 50 | primary cutaneous T-cell non-Hodgkin lymphoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.